Dose rate response of Digital Megavolt Imager detector for flattening filter-free beams

Validation of clearcalc for efficient patient specific QA

Uganda's only radiotherapy center is a very busy facility treating about 210 patients daily on three linear accelerators making it sometimes hard to have machine time for pretreatment QAs. This study was aimed at validating an independent calculation software, ClearCalc (ICS) for second checks of the treatment planning system (TPS) calculations. The validation of ICS started with simple phantom test plans consisting of square, irregular, open and wedged fields designed in the TPS and measured in phantoms. Doses and monitor units (MUs) calculated by ICS were compared with TPS calculated doses and with measured doses. ICS was then validated on clinically approved treatment plans: comparison with TPS calculations and with pretreatment QA measurements performed with electronic portal imaging devices (EPIDs) and analyzed using Gamma passing criteria of 3%/3 mm and 3%/2 mm. Results for test plans were within the passing level of 3.0% except for 2 outliers (-3.1% and 3.1%). As for the clinically approved treatment plans, they show good agreement between MUs (0.2 ± 1.8%), reference point doses (0.2 ±1.5%) and mean PTV doses (0.5 ± 1.4%). ICS calculated (3D) mean gamma pass rates were 98.1±1.6% and 98.4±1.0% for 3%/2 mm and 3%/3 mm criteria. No correlation was seen between gamma analysis results from ICS and EPID. This study validated ClearCalc on phantom and clinically approved plans. The result show that ICS based patients specific QA is quick, promising and potentially allows significant time saving that can be utilized for patient treatments.

Small field measurements using electronic portal imaging device

Purpose/Objective. Small-field measurement poses challenges. Although many high-resolution detectors are commercially available, the EPID for small-field dosimetry remains underexplored. This study aimed to evaluate the performance of EPID for small-field measurements and to derive tailored correction factors for precise small-field dosimetry verification.Material/Methods. Six high-resolution radiation detectors, including W2 and W1 plastic scintillators, Edge-detector, microSilicon, microDiamond and EPID were utilized. The output factors, depth doses and profiles, were measured for various beam energies (6 MV-FF, 6 MV-FFF, 10 MV-FF, and 10 MV-FFF) and field sizes (10 × 10 cm2, 5 × 5 cm2, 4 × 4 cm2, 3 × 3 cm2, 2 × 2 cm2, 1 × 1 cm2, 0.5 × 0.5 cm2) using a Varian Truebeam linear accelerator. During measurements, acrylic plates of appropriate depth were placed on the EPID, while a 3D water tank was used with five-point detectors. EPID measured data were compared with W2 plastic scintillator and measurements from other high-resolution detectors. The analysis included percentage deviations in output factors, differences in percentage for PDD and for the profiles, FWHM, maximum difference in the flat region, penumbra, and 1D gamma were analyzed. The output factor and depth dose ratios were fitted using exponential functions and fractional polynomial fitting in STATA 16.2, with W2 scintillator as reference, and corresponding formulae were obtained. The established correction factors were validated using two Truebeam machines.Results. When comparing EPID and W2-PSD across all field-sizes and energies, the deviation for output factors ranged from 1% to 15%. Depth doses, the percentage difference beyond dmax ranged from 1% to 19%. For profiles, maximum of 4% was observed in the 100%-80% region. The correction factor formulae were validated with two independent EPIDs and closely matched within 3%.Conclusion. EPID can effectively serve as small-field dosimetry verification tool with appropriate correction factors.

Commissioning and clinical evaluation of a novel high-resolution quality assurance digital detector array for SRS and SBRT

PURPOSE

We aimed to perform the commissioning and clinical evaluation of myQA SRS detector array for patient-specific quality assurance (PSQA) of stereotactic radiosurgery (SRS)/ stereotactic body radiotherapy (SBRT) plans.

METHODS

To perform the commissioning of myQA SRS, its dose linearity, dose-rate dependence, angular dependence, and field-size dependence were investigated. Ten SBRT plans were selected for clinical evaluation: 1) Common clinical deviations based on the original SBRT plan (Plan0), including multileaf collimator (MLC) positioning deviation and treatment positioning deviation were introduced. 2) Compared the performance of the myQA SRS and a high-resolution EPID dosimetry system in PSQA measurement for the SBRT plans. Evaluation parameters include gamma passing rate (GPR) and distance-to-agreement (DTA) pass rate (DPR).

RESULTS

The dose linearity, angle dependence, and field-size dependence of myQA SRS system exhibit excellent performance. The myQA SRS is highly sensitive in the detection of MLC deviations. The GPR of (3%/1 mm) decreases from 90.4% of the original plan to 72.7%/62.9% with an MLC outward/inward deviation of 3 mm. Additionally, when the setup error deviates by 1 mm in the X, Y, and Z directions with the GPR of (3%/1 mm) decreasing by an average of -20.9%, -25.7%, and -24.7%, respectively, and DPR (1 mm) decreasing by an average of -33.7%, -32.9%, and -29.8%. Additionally, the myQA SRS has a slightly higher GPR than EPID for PSQA, However, the difference is not statistically significant with the GPR of (3%/1 mm) of (average 90.4%% vs. 90.1%, p = 0.414).

CONCLUSION

Dosimetry characteristics of the myQA SRS device meets the accuracy and sensitivity requirement of PSQA for SRS/SBRT treatment. The dose rate dependence should be adequately calibrated before its application and a more stringent GPR (3%/1 mm) evaluation criterion is suggested when it is used for SRS/SBRT QA.

Determination of the electronic portal imaging device pixel‐sensitivity‐map for quality assurance applications. Part 2: Photon beam dependence

Purpose

Methods

Results

Conclusion

Verification of an optimizer algorithm by the beam delivery evaluation of intensity-modulated arc therapy plans

Background

In the case of dynamic radiotherapy plans, the fractionation schemes can have dosimetric effects. Our goal was to define the effect of the fraction dose on the plan quality and the beam delivery.

Materials and methods

Treatment plans were created for 5 early-stage lung cancer patients with different dose schedules. The planned total dose was 60 Gy, fraction dose was 2 Gy, 3 Gy, 5 Gy, 12 Gy and 20 Gy. Additionally renormalized plans were created by changing the prescribed fraction dose after optimization. The dosimetric parameters and the beam delivery parameters were collected to define the plan quality and the complexity of the treatment plans. The accuracy of dose delivery was verified with dose measurements using electronic portal imaging device (EPID).

Results

The plan quality was independent from the used fractionation scheme. The fraction dose could be changed safely after the optimization, the delivery accuracy of the treatment plans with changed prescribed dose was not lower. According to EPID based measurements, the high fraction dose and dose rate caused the saturation of the detector, which lowered the gamma passing rate. The aperture complexity score, the gantry speed and the dose rate changes were not predicting factors for the gamma passing rate values.

Conclusions

The plan quality and the delivery accuracy are independent from the fraction dose, moreover the fraction dose can be changed safely after the dose optimization. The saturation effect of the EPID has to be considered when the action limits of the quality assurance system are defined.

Planar EPID-Based Dosimetry for SRS and SRT Patient-Specific QA

The study’s purpose was to develop and validate Electronic Portal Imaging Device (EPID)-based dosimetry for Stereotactic Radiosurgery (SRS) and Stereotactic Radiation Therapy (SRT) patient-specific Quality Assurance (QA). The co-operation between extended Source-to-Imager Distance (SID) to reduce the saturation effect and simplify the EPID-based dosimetry model was used to perform patient-specific QA in SRS and SRT plans. The four parameters were included for converting the image to dose at depth 10 cm; dose-response linearity with MU, beam profile correction, collimator scatter and water kernel. The model accuracy was validated with 10 SRS/SRT plans. The traditional diode arrays with MapCHECK were also used to perform patient-specific QA for assuring model accuracy. The 150 cm-SID was found a possibility to reduce the saturation effect. The result of model accuracy was found good agreement between our EPID-based dosimetry and TPS calculation with GPR more than 98% for gamma criteria of 3%/3 mm, more than 95% for gamma criteria of 2%/2 mm, and the results related to the measurement with MapCHECK. This study demonstrated the method to perform SRT and SRT patient-specific QA using EPID-based dosimetry in the FFF beam by co-operating between the extended SID that can reduce the saturation effect and estimate the planar dose distribution with the in-house model.

Dosimetric performance of continuous EPID imaging in stereotactic treatment conditions

PURPOSE

This study aims at investigating the dosimetric characteristics of a Varian aS1000 EPID, focusing on its continuous acquisition mode under the challenging conditions that can be met in stereotactic radiotherapy verification.

METHODS

An aS1000 EPID installed on a Varian TrueBeamSTx was irradiated with 6 and 10 MV unflattened and flattened photon beams. In order to avoid detector saturation, the source-to-detector distance (SDD) was set to 150 or 180 cm depending on the dose rate. EPID image sets were acquired in continuous mode (CM) and also in the commonly used integrated mode (IM) for comparison, to evaluate dose linearity (including dose rate dependence), repeatability, reproducibility, stability, ghosting effect and field size dependence.

RESULTS

CM response linearity was found to be within 0.8% of IM and independent of dose rate. Response repeatability was slightly better for IM and FF beams, being in all cases within 0.9%. Reproducibility was within 0.6% for both modes and all beam qualities. Response stability between continuous frames varied within 1% for dynamic and static irradiations and for all the beam qualities, showing its independence from these parameters. Ghosting effect was not significant, being comparable to signal variations between continuous frames (±1%). Field size dependence in both modes agreed within 1%.

CONCLUSIONS

The dosimetric response of the aS1000 EPID in CM with FFF beams and high dose rates is comparable to that in IM and for flattened beams provided that the appropriate SDD is used. aS1000 EPID in continuous acquisition mode is therefore suitable for stereotactic applications.

Assessing the feasibility of single target radiosurgery quality assurance with portal dosimetry

Purpose

To assess the feasibility of using portal dosimetry (PD) for pre‐treatment quality assurance of single target, flattening filter free (FFF), volumetric arc therapy intracranial radiosurgery plans.

Methods

A PD algorithm was created for a 10X FFF beam on a Varian Edge linear accelerator (Varian Inc, Palo Alto, CA, USA). Treatment plans that were previously evaluated with Gafchromic EBT‐XD (Ashland, Bridgewater, NJ, USA) film were measured via PD and analyzed with the ARIA Portal Dosimetry workspace. Absolute dose evaluation for film and PD was done by computing the mean dose in the region receiving greater than or equal to 90% of the max dose and comparing to the mean dose in the same region calculated by the treatment planning system (TPS). Gamma analysis with 10% threshold and 3%/2 mm passing criteria was performed on film and portal images.

Results

Thirty‐six PD verification plans were delivered and analyzed. The average PD to TPS dose was 0.989 ± 0.01 while film to TPS dose was 1.026 ± 0.01. All PD plans passed the gamma analysis with 100% of points having gamma <1. Overall, PD to TPS dose agreement was found to be target size dependent. As target size decreases, PD to TPS dose ratio decreased from 1.004 for targets with diameters between 15–31 mm and 0.978 for targets with diameters less than 15 mm.

Conclusion

The agreement of PD to TPS mean dose in the high dose region was found to be dependent on target size. Film measurements did not exhibit size dependence. All PD plans passed the 3%/2 mm gamma analysis, but caution should be used when using PD to assess overall dosimetric accuracy of the treatment plan for small targets.